VAXINE
Vaxine was incorporated in 2002 as an Australian biotechnology company focussing on development of innovative vaccine technologies, with its lead product being its Advax delta inulin adjuvant. Supported by funding contracts from the National Institutes of Health Vaxine has developed a board range of vaccines, all utilizing its Advax adjuvant technology for enhanced immunogenicity and protection. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy. Vaxine also has a veterinary division that is commercialising vaccine adjuvants tailored to specific animal health problems.
VAXINE
Social Links:
Industry:
Biotechnology
Founded:
2002-01-01
Address:
Adelaide, South Australia, Australia
Country:
Australia
Website Url:
http://www.vaxine.net
Total Employee:
11+
Status:
Active
Contact:
+61 (0) 8 82044572
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API WordPress Content Delivery Network LetsEncrypt SSL By Default Font Awesome
Similar Organizations
Affinity Biosciences
Affinity Biosciences is an Australian biotechnology company.
Factor Therapeutics Ltd.
Factor Therapeutics Ltd. is an Australian biotechnology company
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.vaxine.net
- Host name: 192.0.78.251
- IP address: 192.0.78.251
- Location: San Francisco United States
- Latitude: 37.7506
- Longitude: -122.4121
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94110
More informations about "Vaxine"
Vaxine
Vaxine is a leading Australian biotechnology company located in Adelaide, South Australia. We produce vaccines and immunotherapies, including vaccines against Covid-19, influenza, …See details»
Projects – Vaxine
Jun 17, 2024 · Vaxine has a long history of coronavirus vaccine development supported by almost two decades of competitive research funding from the US National Institutes of Health. In July 2020, its protein-based vaccine became …See details»
Clinical development of SpikoGen®, an Advax-CpG55.2 …
Jun 5, 2024 · SpikoGen® is a recombinant spike protein trimer manufactured in insect cells and formulated with Advax-CpG55.2 adjuvant. In murine, hamster, ferret and non-human primate …See details»
Full article: Vaxine - Taylor & Francis Online
Aug 3, 2016 · Vaxine, over the last 8 y has successfully executed more than 10 vaccine trials involving its Advaxâ„¢ adjuvant technology. These have included multiple different seasonal …See details»
COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non …
Aug 9, 2021 · To design a recombinant protein-based COVID-19 vaccine, Vaxine pty Ltd used computer models of the spike protein and its human receptor, ACE2, to identify how the virus …See details»
Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2
Nov 22, 2023 · 4 Vaxine Pty Ltd., Bedford Park, Adelaide, SA 5042, Australia. Electronic address: [email protected]. The ongoing evolution of SARS-CoV-2 variants emphasizes the …See details»
COVAX-19Ⓡ Vaccine: Completely blocks virus ... - ScienceDirect
Dec 1, 2021 · To design a recombinant protein-based COVID-19 vaccine, Vaxine pty Ltd used computer models of the spike protein and its human receptor, ACE2, to identify how the virus …See details»
Vaxine to seek Australian approval for protein subunit …
Nov 9, 2021 · Vaxine is looking to bring its Australia-developed Covid-19 vaccine home. The Adelaide-based company is aiming to file for provisional approval of its protein subunit Covid-19 vaccine SpikoGen to the Australian Therapeutic …See details»
Vaxine and Medytox – COVAX-19® - genengnews.com
May 27, 2020 · Type: Vaccine against COVID-19 based on Vaxine’s Advaxâ„¢ non-inflammatory Advax-CpG55.2 adjuvant platform, designed to strongly stimulate both T cell and antibody …See details»
In Iran, an Aussie startup hopes for COVID-19 vaccine success
Jul 4, 2021 · Vaxine, which was founded in 2002, works on vaccine development for a range of diseases. The company has pushed hard for smaller businesses to have more involvement in …See details»
COVAX-19 - Wikipedia
COVAX-19 (or SpikoGen) is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine, in collaboration with CinnaGen, a private company …See details»
An Advax-CpG55.2â„¢ adjuvanted recombinant spike protein
Jul 19, 2023 · Traditional protein-based vaccine approaches to COVID-19 were overshadowed by the new mRNA and adenoviral vector vaccine approaches which were first to receive …See details»
172 countries and multiple candidate vaccines engaged in COVID …
Aug 24, 2020 · 172 economies are now engaged in discussions to potentially participate in COVAX, a global initiative aimed at working with vaccine manufacturers to provide countries …See details»
Mucosal immunization with a delta-inulin adjuvanted ... - Nature
Nov 21, 2022 · In this study we performed in-depth analysis of the immune responses in mice to a subunit recombinant spike protein vaccine formulated with the delta-inulin adjuvant Advax …See details»
Study of immunogenicity and efficacy against Omicron BA.5 of ...
Jan 24, 2024 · Conclusions: Advax-adjuvanted monovalent or bivalent recombinant spike protein vaccines given via parenteral and/or mucosal routes protected against a heterologous BA.5 …See details»
Clinical development of SpikoGen®, an Advax-CpG55.2 …
SpikoGen® is a recombinant spike protein trimer manufactured in insect cells and formulated with Advax-CpG55.2 adjuvant. In murine, hamster, ferret and non-human primate studies, …See details»
COVAX Announces new agreement, plans for first deliveries
Jan 22, 2021 · COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution …See details»
COVAX Announces additional deals to access promising COVID-19 …
Dec 18, 2020 · At least 1.3 billion donor-funded doses will be made available to 92 economies eligible for the Gavi COVAX AMC, targeting up to 20% population coverage by the end of the …See details»
New data suggests Canada's 'gamble' on delaying, mixing and
Oct 9, 2021 · New Canadian data suggests the strategy to delay and mix second doses of COVID-19 vaccines led to strong protection from infection, hospitalization and death — even …See details»
Canada's deliveries from COVAX join growing list of COVID-19 …
Feb 3, 2021 · The global vaccine-sharing initiative known as COVAX told Canada last week it could expect to receive between 1.9 million and 3.2 million doses of AstraZeneca's COVID-19 …See details»